生物制药公司Sionna Therapeutics宣布，其针对囊性纤维化治疗的精准CF二期a阶段临床试验已完成患者入组。该试验重点评估在标准疗法基础上加用Nbd1稳定剂Sion-719的疗效与安全性。
作为针对囊性纤维化根本病因的创新疗法，Sion-719通过稳定CFTR蛋白的Nbd1结构域发挥作用。此次试验采用精准医疗策略，旨在为特定患者群体探索更有效的治疗方案。
临床试验的顺利推进标志着Sionna Therapeutics在呼吸系统疾病治疗领域取得重要进展。公司将持续关注试验数据，为后续研发决策提供科学依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.